While the market for active pharmaceutical ingredients (APIs) has been highly profitable, it faces key challenges. Increasing regulatory forces, the stronger bargaining power of buyers, rising costs, low-cost competition from Asian suppliers, delayed drug approvals, and drug failures are creating challenges for research-driven pharmaceutical companies, generic drug firms, and contract manufacturers. These changes require more than just compliance with specifications. Process understanding is the key to moving from corrective actions to more efficient continuous improvements.
Operational excellence (OPEX) model
To address thee changes, we developed a reference model (OPEX) to effectively implement the modern principles of operational excellence. This reference model was developed by analyzing current integrated production systems from the automotive industry and adapting them to the pharmaceutical industry. The OPEX model consists of three parts: total productive maintenance (TPM), total quality management (TQM), and just-in-time (JIT) inventories.The main objective of the TPM system is to provide efficient management of fixed assets and to effectively use new process technologies. The goal of the TQM system is to significantly increase quality performance (e.g., reduce variability, scrap rates, and complaint rates). And JIT focuses on reducing working capital by simultaneously increasing service levels. In the OPEX model, the management system has to support all activities supporting operational excellence. Only by coordinating all these elements (TPM, TQM, and JIT) can an API manufacturing site reach top performance.
Benchmarking API manufacturing plants
The study showed that the total number of employees is not directly correlated with results in quality assurance and control. Quality cannot be inspected into a product. In contrast, built-in quality, which is a process improvement, leads directly to lower scrap rates. Consequently, costs are decreasing, and value is being added.
The study also showed that key performance indicators (KPIs) at API plants either were missing or not clearly defined. Only by implementing operational excellence initiatives and controlling them through KPIs can API sites be prepared for the challenges facing API manufacturers. If the culture and management, however, does not support these improvement activities, even the best initiatives will fail.
In addition to this benchmarking study for the pharmaceutical and API industries, the understanding of operations in pharmaceuticals may be deepened by several research and industry projects such as implementing customized integrated productions systems for pharmaceutical plants. Experiences of other industries and discussions with site leaders show that implementing only single tools such as Six Sigma and total productive maintenance does not lead to sustainable success. Integrated production systems and the interdependencies of key performance indicators are crucial success factors. These lessons are important for Western pharmaceutical companies in reaching operational excellence and achieving future competitive advantage.
Thomas Friedli, PhD, is a professor, and Thomas Gronauer* and Daniel Tykal are research associates, Institute of Technology Management at the University of St. Gallen, Dufourstrasse 40a I CH-9000 St. Gallen, Switzerland, tel. +41(0)71 224 7269 ; fax +41(0)71 224 7311, email@example.com